Key points are not available for this paper at this time.
Gemtuzumab ozogamicin (GO; Mylotarg; Wyeth, PA) is a humanized anti-CD33 antibody conjugated to the cytotoxic agent calicheamicin. Although the efficacy of this agent is now being explored in phase 3 trials, there is significant concern about the risk of hepatic injury consequent on exposure to GO,
Versluys et al. (2004) studied this question.